Steven Cohn

Emailsmcohnutmbedu

Research activity per year

Research Strategic Pillar

Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):

Research Strategic Pillar Keywords

Specialized Health

Fingerprint

Dive into the research topics where Steven Cohn is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Finished
4 Active

A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 for Induction, Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.
Cohn, S. (PI)
Reistone Biopharma Company Limited
1/19/22 → 1/18/27
Project: Research project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S. (PI)
Eli Lilly and Company
5/13/20 → 5/12/25
Project: Research project
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.
Cohn, S. (PI)
Eli Lilly
2/27/20 → 2/26/25
Project: Research project
Corrona Inflammatory Bowel Disease (IBD) Registry
Cohn, S. (PI)
CorEvitas, LLC
5/21/19 → 4/15/25
Project: Research project
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Cohn, S. (PI)
Eli Lilly
8/20/20 → 3/31/23
Project: Research project

43 Article
2 Chapter
1 Review article

GPR120 Inhibits Colitis Through Regulation of CD4⁺ T Cell Interleukin 10 Production
Yang, W., Liu, H., Xu, L., Yu, T., Zhao, X., Yao, S., Zhao, Q., Barnes, S., Cohn, S. M., Dann, S. M., Zhang, H., Zuo, X., Li, Y. & Cong, Y., Jan 2022, In: Gastroenterology. 162, 1, p. 150-165 16 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Restarting elective endoscopy safely amidst an evolving pandemic and the impact of patient perception
Nguyen, C., Kline, K. T., Merwat, S., Merwat, S., Luthra, G., Parupudi, S. & Cohn, S., Dec 2021, In: BMC Gastroenterology. 21, 1, 344.
Research output: Contribution to journal › Article › peer-review

Open Access
AIDS-associated Esophageal Plasmablastic Lymphoma
Abdulla, H. M. & Cohn, S., Jan 2021, In: Clinical Gastroenterology and Hepatology. 19, 1, p. A18
Research output: Contribution to journal › Article › peer-review
Patients with gastric antral vascular ectasia (Gave) are at a higher risk of gastrointestinal bleeding in the absence of cirrhosis
Wang, J., Stine, J. G., Cornella, S. L., Argo, C. K. & Cohn, S. M., 2015, In: Journal of Clinical and Translational Hepatology. 3, 4, p. 254-259 6 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways
Brodrick, B., Vidrich, A., Porter, E., Bradley, L., Buzan, J. M. & Cohn, S. M., May 27 2011, In: Journal of Biological Chemistry. 286, 21, p. 18515-18525 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
16 Scopus citations

Steven Cohn, MD, PhD, AGAF, FACG

Personal profile

Research Strategic Pillar

Research Strategic Pillar Keywords

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 for Induction, Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.

Corrona Inflammatory Bowel Disease (IBD) Registry

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

GPR120 Inhibits Colitis Through Regulation of CD4⁺ T Cell Interleukin 10 Production

Restarting elective endoscopy safely amidst an evolving pandemic and the impact of patient perception

AIDS-associated Esophageal Plasmablastic Lymphoma

Patients with gastric antral vascular ectasia (Gave) are at a higher risk of gastrointestinal bleeding in the absence of cirrhosis

Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways

Steven Cohn, MD, PhD, AGAF, FACG

Personal profile

Research Strategic Pillar

Research Strategic Pillar Keywords

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output